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ed work was part of MsSummary Late allergic reactions (LAR) following allergen challenge occur in
different compartments. We studied the kinetics of nasal and bronchial nitric oxide
(NO) in mild asthmatics after allergen challenge.
Twelve males with intermittent asthma (28 yr, FEV1 97% of predicted, PC20
methacholine o8mg/ml) and known LAR after bronchial allergen challenge
underwent nasal and bronchial allergen provocation using the same allergen
separated by a washout of 3 weeks. Nasal and bronchial NO were measured before
challenge, during early (EAR) and late phase reactions, and 24 h after allergen.
The mean (SEM) maximum fall of FEV1 at EAR was 31.973.2% (P ¼ 0:001), and
17.672.2% (P ¼ 0:004) during LAR. All patients developed nasal EAR (max. fall in
nasal rhinomanometric flow 64.877.6% of baseline) after nasal challenge, and 10
patients demonstrated nasal LAR with a fall in nasal flow of 65.976.6% (both
P ¼ 0:002, respectively). During EAR, there was stronger reduction of nasal
(19:2 6:2%; P ¼ 0:039) than bronchial NO (6.975.2% of baseline, P ¼ ns). In
contrast, bronchial NO also tended to decrease during bronchial LAR
(8:8 6:8%; P ¼ ns), while nasal NO slightly increased non-significantly
(+17710.8%, P ¼ ns). After 24 h, bronchial NO was significantly elevated
(+78.1740.1%, P ¼ 0:039), whereas nasal NO was unchanged (+6.1715.1%,
P ¼ ns). The intraindividual difference between bronchial and nasal changes of NO
during LAR, but not EAR or after 24 h, was significant (lung vs. nose: 35.6714.1%
relative difference, P ¼ 0:039).
Despite similar functional responses in nose and bronchi, nasal NO kinetics
following allergen challenge differ from bronchial NO. The concise mechanisms
accounting for this discrepancy warrant further investigations.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Allergic rhinitis and asthma share several patho-
physiologic features, and these similarities have led
to the introduction of a unified concept of
’ ’
united
airways’’.1,2 Allergic reactions in the lung and nose
involve many of the same inflammatory cells and
mediators.3 There has been intense research into
monitoring of inflammation in asthma and rhinitis.
In this regard, nitric oxide (NO) has been studied as
a marker of eosinophilic airway inflammation.4–9
Exhaled NO is elevated in the airways of stable
asthmatics and has been shown to increase follow-
ing bronchial allergen challenge.6 Despite the
general utility of NO in asthma, various factors
influence NO levels in exhaled breath, including
airway narrowing,10,11 caffeine12 or hypertonic
saline inhalation.6,11,13 Nasal NO is increased in
subjects with seasonal14 or perennial15 allergic
rhinitis and responds to topical corticosteroid
therapy.16 However, the kinetics of nasal NO
following allergen challenge have been studied
only to a minor extent.17
To the best of our knowledge, there are no
studies directly comparing the kinetics of nasal and
bronchial NO in the same subject after allergen
challenge. This study therefore compares nasal and
bronchial NO kinetics during early (EAR) and late
phase allergic reactions (LAR) in patients with both
asthma and rhinitis.Materials and methods
Patients
Twelve males (median age 27.5 years) with a
history of allergic rhinitis and intermittent asthma
(mean FEV1 97% of predicted; PC20 methacholine
o8mg/ml,16,18 only short-acting beta-agonist prn)
sensitized (skin test and specific IgE) to grass pollen
(n ¼ 9), house dust mite (2) and horse dander (1)
were studied. All patients were non-smokers who
had demonstrated dual asthmatic reactions follow-
ing allergen inhalation on a prior occasion. None of
the patients used anti-inflammatory drugs. Sub-
jects gave written informed consent and the
study was approved by the local hospital ethics
committee.
Study design and measurements
The study was performed outside the pollen season.
At baseline, a bronchial allergen challenge was
performed according to a method described byTaylor et al.16,19 using a five-breath dosimeter
protocol (MEFAR nebulizer, Markos, Monza, Italy).
A single bolus of allergen (ALK, Hamburg, Germany)
was administered at a calculated (historic) dose
(PD20) that had resulted in a dual response on a
previous occasion using an incremental allergen
challenge.16,19 Serial spirometry was performed
using the Masterscope system (Jaeger; Wu¨rzburg,
Germany) according to ATS.20 Exhaled NO was
measured prior to challenge, at the peak of EAR
and LAR and 24 h after allergen.
After a washout of 3 weeks, nasal allergen
challenge was performed with the same allergen
according to the EAACI guidelines.28 Responses
were evaluated every 15min after allergen admin-
istration and considered positive when symptoms
occurred.29 Nasal EAR was defined as a flow
reduction 440% (150 Pa, within 30min after aller-
gen). Nasal LAR was defined as delayed (3–8 h after
allergen) occurrence of symptoms accompanied by
an at least 30% decrease of nasal flow. Nasal flow
and resistance were measured by active anterior
rhinomanometry (Jaeger; Wu¨rzburg, Germany).21
Nasal NO was measured prior to and during EAR,
LAR, and 24 h after nasal allergen.Exhaled bronchial and nasal NO
Exhaled NO was measured by a chemiluminescence
analyzer (ECOmedics CLD88sp) according to Eur-
opean Respiratory Society (ERS) and ATS guidelines
for the measurement of exhaled NO.11,22 Nasal NO
was measured according to ATS guidelines.11 The
patient exhaled against expiratory resistance while
targeting a mouth pressure of 10 cm H2O to close
the velum, with a nasal olive introduced into one
nostril and air aspirated from the nasal cavity at
constant flow (50ml/s) via the olive by a suction
pump. The mean of three measurements was
recorded, respectively.Statistical analysis
Unless otherwise stated, data are presented as
arithmetic mean values with standard error of
mean (SEM). Due to technical problems, rhinomano-
metry could not be performed in one patient.
Changes of NO levels between lung and nose were
compared intraindividually using pairwise compar-
isons based on nonparametric sign tests with P
valueso0.05 indicating significance. Individual
changes of nasal or bronchial NO compared to
baseline values were analyzed by paired signed
test. Correlations between bronchial and nasal NO
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Figure 1 Bronchial and nasal NO kinetics after allergen
challenge. Plots represent mean (+SEM) values for
individual changes (% of baseline) of bronchial (bold
square) and nasal (open circle) NO during early (EAR),
and late phase reaction (LAR), and 24 h after allergen
challenge. *P ¼ 0:039 nose vs. lung, **Po0:05 vs.
corresponding baseline value.Results
A summary of baseline characteristics of sub-
jects is presented in Table 1. All subjects deve-
loped bronchial and nasal EAR with a mean
maximum fall in FEV1 of 31.973.2% (P ¼ 0:001)
and nasal flow reduction of 64.877.6% (P ¼ 0:002)
of baseline. The mean bronchial LAR was a fall
in FEV1 of 17.672.2% (P ¼ 0:004) of baseline.
Ten patients also developed nasal LAR with a
maximum flow reduction 65.976.6% (P ¼ 0:002)
of baseline.
Bronchial NO decreased non-significantly during
EAR from 71721 to 61717 ppb, (P ¼ ns), equalling
a mean NO reduction of –6.9275.22% from base-
line. There was a further decrease in bronchial NO
during LAR to 59716 ppb (P ¼ 0:146 vs. baseline,
mean decline of –8.8076.77%). In contrast, ex-
haled bronchial NO increased significantly 24 h
after bronchial allergen challenge to 95723 pbb
(P ¼ 0:039 vs. baseline, mean rise of 78.1740.1%).
Nasal challenge with allergen caused a decrease
in nasal NO during EAR from 8577 to 6879 ppb
(P ¼ 0:039, mean reduction of 19.276.2% from
baseline). In contrast, nasal NO slightly increased
non-significantly during LAR to 9577 ppb (P ¼ 0:74,
mean increase 17710.8%), while levels returned to
baseline after 24 h (85712 ppb; P ¼ 0:63, mean
change 6.1715.1%) (Fig. 1).
On an individual basis, there was no significant
difference between bronchial and nasal NO changes
during EAR (lung–nose: 5.777%, P ¼ ns). In con-
trast, significant discrepancies were observed dur-
ing LAR (lung–nose: 35.6714.1%, P ¼ 0:039).Table 1 Summary: patient baseline characteris-
tics.
Age (years)
Median (interquartile range) 28 (26–34)
FEV1 (% of predicted)
Mean (SD) 97 (5)
Allergen (n)
Grass 9
House dust mite 2
Horse dander 1
RAST class
Median (range) 3 (2–6)After 24 h, there was a trend towards increased
bronchial compared to nasal NO levels (lung–nose:
40.6731.3%, P ¼ ns).
At baseline, exhaled bronchial NO was strongly
correlated with nasal NO (r ¼ 0:71, P ¼ 0:02).
However, there was no further correlation of
bronchial or nasal NO with either corresponding
changes in lung or nose, respectively, or changes in
bronchial or nasal airflow during EAR or LAR (all
correlations P40:05).Discussion
To the best of our knowledge, individual compar-
isons of bronchial and nasal NO kinetics have not
previously been reported and ours is the first study
that systematically investigates whether or not
nasal and bronchial NO kinetics after local allergen
challenge are similar. In the present study, we
describe dissimilarities between nasal and bron-
chial NO kinetics after allergen challenge in atopic
patients with both asthma and rhinitis. Levels of
both bronchial and nasal NO decreased during EAR.
With regard to bronchial NO, this observation is
consistent with a previous study by Dweik et al.23
Adding to this, a decrease of nasal NO during EAR
has also been described by Silkoff et al.17 This
reduction of exhaled NO may be a consequence of
the allergen-induced reduction in airflow as pre-
viously demonstrated by others.24–26 Nasal NO
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However, there was no correlation between nasal
or bronchial NO and nasal or bronchial flow
reduction during EAR, hence the observed reduc-
tion of NO cannot be fully explained by airway
obstruction. Decreased expired NO during EAR may
also reflect rapid consumption of NO to form stable
nitrogen intermediates, e.g. peroxynitrite or ni-
trate.23 It has been demonstrated that early
antigen challenge results in an immediate release
of airway superoxide anion, thus promoting the
formation of peroxynitrite through NO and O2-.
23
During bronchial LAR, exhaled NO levels also
tended to decrease or remain stable in all patients.
At first glance, this finding was somewhat surpris-
ing, since late phase allergic reactions are usually
associated with airway eosinophilia and increased
NO levels,28 despite airway obstruction. However,
the majority of our patients displayed LAR at an
relatively early timepoint (between 3 and 5 h post
challenge), therefore it can be speculated that an
early influx of neutrophils during the initial stages
of LAR29,30 might have partially contributed to the
failure to find increased bronchial NO during LAR,
since NO levels can be decreased by superoxide
generated from neutrophils.31
In contrast, nasal NO increased during nasal
LAR, and the individual rise of nasal NO was
significant compared to bronchial NO. The reasons
for this discrepancy are not fully clear, in particular
since there was a marked reduction in nasal flow
during LAR. Hence, the observed NO levels are
rather an underestimation of
’ ’
true’’ nasal NO, as
demonstrated by Djupesland et al.27 On the other
hand, it might be argued that the magnitude of
eosinophilic nasal inflammation and NO release
overcomes NO reduction by decreased nasal flow,
thus resulting in a net increase of NO. Pastorello et
al.5 demonstrated that large numbers of eosino-
phils appear in nasal lavage fluid rapidly after
allergen challenge, peak at 8 h and tend to
normalize after 24 h.
Bronchial NO significantly increased 24 h after
allergen, which is consistent with earlier reports.28
We therefore hypothesize that the discrepant nasal
and bronchial NO levels are probably at least in
part due to the fact that eosinophilic inflammation
after allergen challenge in the lung is fully
established at a later timepoint compared to the
nasal compartment.
In conclusion, our study demonstrates similar
nasal and bronchial NO kinetics during early, but
not late, allergic responses in subjects with both
rhinitis and asthma. Further studies need to clarify
the relation of nasal and bronchial NO to inflam-
matory cells and mediators.Acknowledgements
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